Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning

Project Information

ProSCAN

Grant agreement ID: 190185443

DOI 10.3030/190185443

Project closed

EC signature date 30 March 2022

Start date 1 October 2021

End date 29 February 2024

Funded under

• The European Innovation Council (EIC)

Total cost € 2 839 125,00

EU contribution € 1 987 387,00

Coordinated by

GLYCANOSTICS SRO
Slovakia

Project description

Innovative glycan-based early diagnostic method for prostate cancer

Prostate cancer (PC) is the second most frequent malignancy in men; only in 2020, 1.4 million new cases and 0.4 million deaths were registered worldwide. The chances of survival depend on the cancer stage at the time of diagnosis. The development of early diagnostics is therefore critically important; nearly 50 % of PC patients will survive their cancer for 5 years or more after they are diagnosed at an early stage. The EU-funded ProSCAN project aims to validate and register a non-invasive liquid biopsy PC diagnostic test with an accuracy of up to 90 %. ProSCAN is the first early stage PC test based on glycan analysis in the blood and will identify men at high risk of PC, referring them for a confirmatory biopsy.

Objective

Prostate cancer (PCa) is the 2nd most frequent cancer in men with 1.4M new annual cases and nearly 0.4M deaths worldwide in 2020. PCa incidence is expected to increase to 2.1M cases and 0.6M annual deaths by 2035. Statistically, 1 in 8 men will get PCa in their lifetime. However, nearly 50% of cancer deaths may be avoided if PCa were detected at early stages. Survival is proportional to the stage reached at the time of diagnosis - hence early-stage diagnostics is key to reduce mortality. Our aim is to clinically validate & register ProSCAN, an affordable, non-invasive next-generation liquid biopsy PCa diagnostic test with a final accuracy of up to 90%. The ProSCAN is the first test for early-stage PCa diagnostics based on glycan analysis in blood. ProSCAN will identify healthy men and those at risk of PCa, who need a confirmatory biopsy. Being so accurate, ProSCAN will eliminate ~1.6 M of avoidable biopsies with the cost of ~1.5bn (in the EU and the US alone).

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• natural sciences › biological sciences › biochemistry › biomolecules › carbohydrates
• medical and health sciences › clinical medicine › oncology

You need to log in or register to use this function

Keywords

• early diagnostics
• biotechnology
• glycan-based test
• prostate cancer
• health innovation
• bionanotechnology

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
• HORIZON.3.1.2 - The Accelerator

Topic(s)

• HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01 - Strategic Digital and Health Technologies

Call for proposal

HORIZON-EIC-2021-ACCELERATORCHALLENGES-01

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Coordinator

GLYCANOSTICS SRO

• Net EU contribution: € 1 987 387,00
• Address: KUDLAKOVA 1848/7 ; 841 01 Bratislava ; Slovakia
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Slovensko › Bratislavský kraj › Bratislavský kraj
• Region: Slovensko › Bratislavský kraj › Bratislavský kraj
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 2 839 125,00